First Citizens Bank & Trust’s Anika Therapeutics ANIK Stock Holding History

First Citizens Bank & Trust’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-4,999	Closed	-$245K	–	473
2016 Q4	$245K	Sell	4,999 -2,250	-31%	-$104K	0.03%	398
2016 Q3	$347K	Sell	7,249 -5,637	-44%	-$278K	0.03%	365
2016 Q2	$691K	Sell	12,886 -1,246	-9%	-$58.7K	0.06%	204
2016 Q1	$632K	Buy	+14,132	New	+$573K	0.05%	219

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First Citizens Bank & Trust's ANIK Position: Q1 2017 in Review

First Citizens Bank & Trust sold out of Anika Therapeutics (ANIK) in Q1 2017, closing a stake of 4,999 shares — an estimated $245K sold.

First Citizens Bank & Trust first reported a position in ANIK in Q1 2016 and held it in 4 quarters. The position peaked at $691K in Q2 2016. 156 funds tracked by Wall St. Rank hold ANIK as of Q1 2017.

First Citizens Bank & Trust reported no remaining Anika Therapeutics position as of Q1 2017 after selling out during the quarter.
First Citizens Bank & Trust sold 4,999 Anika Therapeutics shares in Q1 2017, an estimated $245K.
First Citizens Bank & Trust first reported a position in Anika Therapeutics in Q1 2016 and held it in 4 quarters.
First Citizens Bank & Trust's Anika Therapeutics position peaked at $691K in Q2 2016.
156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2017.

Based on First Citizens Bank & Trust's 13F filing for Q1 2017, filed 25 Apr 2017.